Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney transplants: a smarter way to dose Anti-Infectives?

NCT ID NCT07765615

Knowledge-focused Sponsor: Zhongnan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study explores whether tracking rapid changes in kidney function right after a kidney transplant can help doctors choose the right dose of anti-infective drugs. Currently, dosing relies on static tests that may not reflect the fast shifts in kidney performance during the first days after surgery. By analyzing biomarkers and drug levels, researchers aim to build a model that supports personalized dosing, potentially improving safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Precision dosing strategies for anti-infective agents, guided by dynamic kidney function markers
What this could lead to
If successful, this could lead to safer, more effective anti-infective dosing for kidney transplant patients, reducing complications and improving recovery.
What could go wrong
This is a small, early-stage study focused on modeling and validation, so results may not apply broadly. Individual responses to drugs can vary, and the approach needs further testing before routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

40

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged \>= 18 years old; 2. Patients receiving kidney transplantation within 0-5 days postoperatively; 3. Clinically planned administration of anti-infective agents for perioperative prophylaxis, empirical therapy or confirmed infection treatment, with an anticipated treatment duration of no less than 5 days; 4. Written informed consent obtained from the subject or legal surrogate; 5. Indwelling urinary catheter retained for at least 48 hours postoperatively to facilitate early urine sample collection; 6. Patients anticipated to be free of dialysis requirement with urine output or early graft functional recovery at enrollment. Exclusion Criteria: 1. Previous kidney transplantation or combined multi-organ transplantation 2. Patients requiring continuous renal replacement therapy in the early postoperative period 3. Severe hepatic dysfunction, defined as Child-Pugh class C, or ALT/AST \> 5 times the upper limit of normal accompanied by markedly elevated bilirubin 4. Early postoperative use of ECMO, plasmapheresis or other extracorporeal therapies that substantially alter drug clearance 5. Pregnancy or lactation 6. Subjects judged inappropriate for enrollment by investigators, including those with unfeasible sampling, extremely short expected survival, severe missing clinical data, etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Transplant recipient (kidney) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Transplant recipient (kidney)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.